A message from Soleno Therapeutics to our PWS Community:
FPWR
Recent Posts
Welcome to an inside look at some of the impactful research taking place to improve the lives of individuals with Prader–Willi syndrome (PWS). In this interview, four FPWR research team members—Theresa Strong, Lauren Schwartz-Roth, Marc Ridilla, and ...
Topics: Research
Each year, the Foundation for Prader-Willi Research (FPWR) recognizes outstanding individuals who have made a profound difference in the lives of those affected by Prader-Willi syndrome. This year, we are thrilled to honor two remarkable leaders at o...
We’re excited to introduce two new members of the FPWR team: Karla Blair and Nicci Peterson! As parents, advocates, and passionate members of the PWS community, Karla and Nicci bring heartfelt commitment and a personal perspective to our work. Their ...
Topics: News
We recently hosted a webinar featuring Dr. Tien Lee and Dr. Manasi Jaiman of Aardvark Therapeutics. They dove into the science and promise behind ARD‑101—an innovative oral medication aimed at curbing hyperphagia in individuals with Prader‑Willi synd...
A newly published study on the use of guanfacine extended release (GXR) in individuals with Prader-Willi syndrome (PWS) marks an important step forward in addressing challenging behaviors such as aggression, skin-picking, and hyperactivity. Funded by...
Still United, Still Inspired We're still riding the wave of connection, energy, and inspiration from United in Hope 2025! This incredible event brought together three powerful organizations - the Foundation for Prader-Willi Research (FPWR), the Prade...
Did you know that swallowing issues are extremely common in babies with Prader-Willi syndrome (PWS)? A recent study from Cook Children’s Medical Center (CCMC) in Texas took a closer look—and what they found is something every clinician and parent of ...
Topics: Research, Parents, Children 0-3
A new clinical trial aims to provide relief from hyperphagia for people with Prader-Willi Syndrome. HERO is a global Phase 3 clinical trial investigating ARD‑101, an investigational oral medication aimed at reducing hyperphagia. This trial is current...
